Online data supplement
Expression of IL17A in human atherosclerotic lesions is associated with
increased inflammation and plaque vulnerability
Basic Research in Cardiology
Christian Erbel1
Thomas J. Dengler1
Susanne Wangler1
Felix Lasitschka2
Florian Bea1
Nadine Wambsganss1
Maani Hakimi3
Dittmar Böckler3
Hugo A. Katus1
Christian A. Gleissner1
- 1Department of Cardiology, University of Heidelberg, Germany; 2 Institute of Pathology University of Heidelberg, Heidelberg, Germany; 3 Department of
Vascular Surgery, University of Heidelberg, Germany
Corresponding author
Email:
Table A
Primer sequences
ParameterSequence
FP CD3E5'-GATGCAGTCGGGCACTCACT-3'
RP 5'-CATTACCATCTTGCCCCCAA-3',
FPVCAM15'-GGAGAACCCAGATAGACAGCC-3'
RP5'-TGCAGCTTACAGTGACAGAGC-3'
FPIL65'-CAGAAAACAACCTGAACCTTCC-3'
RP5'-GTACTCATCTGCACAGCTCTGG-3',
FPIL215'-CATGGAGAGGATTGTCATCTGTC-3'
RP5'-CAGAAATTCAGGGACCAAGTCAT-3',
FP IL235'-GGACAACAGTCAGTTCTGCTT-3'
RP 5'-CACAGGGCTATCAGCGAGC-3'
FPOPN5'-ACTCGAACGACTCTGATGATGT-3'
RP5'-GTCAGGTCTGCGAAACTTCTTA-3'
IL17A(R&D Systems).
Forward (FP) and reverse primer (RP)
Table B Patients characteristics according to the symptomatic Data are presented as mean ±S.D. or count and percentages.
ParameterAsymptomaticSymptomatic P value
Demographics
No. of Patients35 (44)44 (56)
Age, y73 ±772 ±8n.s.
Female n (%)9 (26)9 (21)n.s.
Risk Factors, n (%)
Hypertension22 (62)33 (75)n.s.
Hypercholesteremia(>200mg/dl)24 (69)24 (55)n.s.
LDL Cholesterol [mg/dl]148.10 ±69.52134.04±59.44n.s.
Hypertriglyceridemia (>150mg/dl)13 (37)19 (43)n.s.
Triglycerides [mg/dl]193.05±147.4195.63 ±124.28 n.s.
Diabetes Mellitus [%] 15 (42)16 (36)n.s.
Medication, n (%)
Acetylsalicylic Acid23 (65)33 (75)n.s.
HMG-CoA Inhibitor 21 (60)25 (57)n.s.
Hematological parameters
Leukocytes [/nl] 8.13 ±1.907.98±2.35n.s.
CRP8.64±11.638.89±9.05n.s.
Uric Acid6.69±1.855.98±1.48 0.058
Fasting Glucose132.55±49.46138.51±55.02n.s.
Table C Patients characteristics according to a medical treatment with or without a HMG-CoA Inhibitor Lipid profile and hematological parameters were measured on the day of operation. Total numbers may not add up to the expected total because of missing data for some variables. Data are presented as mean ± S.D. or count and percentages.
Parameter No HMG-CoA HMG-CoAP value
Reductase Inh. Reductase Inh.
Demographics
No. of Patients24 (34%)46 (66%)
Age, y75 ±771 ±9 n.s.
Female 6 (25%)12 (26%) n.s.
Symptomatic, n (%)
Asymptomatic11 (46%)23 (50%) n.s.
Symptomatic13 (54%)23 (50%) n.s.
Risk Factors, n (%)
Hypertension19 (79%)36 (78%) n.s.
Hypercholesteremia(>200mg/dl)16 (67%)32 (70%) n.s.
Hypertriglyceridemia (>150mg/dl)9 (37%)23 (50%) n.s.
Diabetes Mellitus [%] 11 (45%)19 (41%) n.s.
Medication, n (%)
Acetylsalicylic Acid20 (83%)36 (78%) n.s.
HMG-CoA Reductase Inhibitor 0 (0%)46 (100%) <0.0001
Hematological parameters
Leukocytes [/nl] 7.57±1.887.87±2.03 n.s.
CRP [mg/l]14.98±2.5013.03±13.14 n.s.
Fasting Glucose [mg/dl]140.04±44.14139.57±65.13 n.s.
Uric Acid [mg/dl]6.57±1.845.96±1.55 n.s.
Lipid profile
Total Cholesterol [mg/dl]189.88±52.84193.50±26.15 n.s.
Triglycerides [mg/dl]167.24±72.31202.12±175.29 n.s.
Table D Patients characteristics according to a medical treatment with acetylsalicylic acid or a clopidogrel or vitamin k antagonist Lipid profile and hematological parameters were measured on the day of operation. Total numbers may not add up to the expected total because of missing data for some variables. Data are presented as mean ± S.D. or count and percentages.
ParameterClopidogrel /Acetylsalicylic P value
Vit. K AntagonistAcid
Demographics
No. of Patients14 (20%)56 (80%)
Age, y74 ±872 ±9n.s.
Female 3 (21%)15 (27%)n.s.
Symptomatic
Asymptomatic5 (36%)28 (50%)n.s.
Symptomatic9 (64%)28 (50%)n.s.
Risk Factors, n (%)
Hypertension11 (78%)44 (79%)n.s.
Hypercholesteremia(>200mg/dl)9 (64%)37 (66%)n.s.
Hypertriglyceridemia (>150mg/dl)7 (50%)25 (45%)n.s.
Diabetes Mellitus [%] 4 (29%)26 (46%)n.s.
Medication, n (%)
Acetylsalicylic Acid0 (0%)56 (100%) <0.0001
HMG-CoA Reductase Inhibitor 9 (64%)39 (69%)n.s.
Hematological parameters
Leukocytes [/nl] 7.19±1.568.20±2.23n.s.
CRP [mg/l]6.55±1.2010.82±10.83n.s.
Fasting Glucose [mg/dl]127.17±30.30136.84±54.24n.s.
Uric Acid [mg/dl]6.60±0.986.25±1.82 n.s.
Lipid profile
Total Cholesterol [mg/dl]183.13 ±65.70203.07±45.20 n.s.
Triglycerides [mg/dl]167.43±59.83201.80 ±142.99 n.s.